PLA2R CAART
Alternative Names: Phospholipase A2 receptor Chimeric Autoantibody Receptor T Cells - Cabaletta Bio; PLA2R-CAARTLatest Information Update: 19 May 2022
At a glance
- Originator University of Pennsylvania
- Developer Cabaletta Bio
- Class Gene therapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Kidney disorders